•
Dec 31, 2020
MacroGenics Q4 2020 Earnings Report
MacroGenics reported its Q4 2020 earnings, highlighted by the FDA approval of MARGENZA™ and progress in partnered programs like retifanlimab and teplizumab.
Key Takeaways
MacroGenics announced the FDA approval of MARGENZA™ in December 2020 and anticipates its commercial launch in March 2021. The company also looks forward to potential regulatory decisions for partnered products retifanlimab and teplizumab, with PDUFA target action dates in July 2021. MacroGenics expects to provide clinical updates across its portfolio throughout 2021.
MARGENZA (margetuximab-cmkb) was approved by the FDA in December 2020 for metastatic HER2-positive breast cancer.
Commercial launch of MARGENZA is expected in March 2021.
PDUFA target action dates for partnered products retifanlimab and teplizumab are set for July 2021.
Multiple clinical updates across MacroGenics' portfolio are anticipated in 2021.